載入中
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
前收盤價
US$2.90
+US$0.06 · +2.11%
盤中時間採用ET。市場資料可能有所延遲。
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
日內區間
目前US$2.90
52週區間
目前US$2.90
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
60
合理估值
情緒
42
多空交錯
風險
67
高風險
動能
69
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
日內區間
目前US$2.90
52週區間
目前US$2.90
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4052萬 USD | 3231.4萬 USD | 7812.3萬 USD | 1971.2萬 USD | 2554.4萬 USD |
| 銷貨成本 | — | 1.99億 USD | 606.4萬 USD | 633.7萬 USD | 505.3萬 USD |
| 毛利 | 4052萬 USD | −1.67億 USD | 7205.9萬 USD | 1337.5萬 USD | 2049.1萬 USD |
| 研究與開發 | 8995.3萬 USD | 1.99億 USD | 1.78億 USD | 1.75億 USD | 1.43億 USD |
| 銷售、一般及管理費用 | 4990.3萬 USD | 7198.7萬 USD | 6965.3萬 USD | 7070.4萬 USD | 7618.3萬 USD |
| 營業費用 | 1.4億 USD | 8421.9萬 USD | 2.41億 USD | 2.39億 USD | 2.14億 USD |
| 利息收入 | 831萬 USD | 1406.2萬 USD | 1756.6萬 USD | 551.8萬 USD | 60.7萬 USD |
| 利息支出 | 617.1萬 USD | — | — | — | — |
| 折舊和攤銷 | 527.7萬 USD | 580.9萬 USD | 606.4萬 USD | 633.7萬 USD | 505.3萬 USD |
| 營業利益 | −9933.6萬 USD | −2.51億 USD | −1.69億 USD | −2.26億 USD | −1.93億 USD |
| 淨利 | −1.6億 USD | −2.37億 USD | −1.53億 USD | −2.2億 USD | −1.93億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1496.38萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1217.39萬0.12%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1149.28萬0.01%787.4億 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO366.55萬0.03%139.17億 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF350.52萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB304.82萬0.03%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA198.62萬0.01%218.24億 USD0.03%US$32.79+0.40%
Vanguard Russell 2000 ETFVTWO176.26萬0.01%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
